← Back to Clinical Trials
Recruiting NCT06543732

NCT06543732 Vital@Work: Reintegration Program for Employees with Stress-related Complaints

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06543732
Status Recruiting
Phase
Sponsor Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Condition Return to Work
Study Type INTERVENTIONAL
Enrollment 208 participants
Start Date 2025-01-08
Primary Completion 2026-09-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 68 Years
Study Type INTERVENTIONAL
Interventions
Return to work program

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 208 participants in total. It began in 2025-01-08 with a primary completion date of 2026-09-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The objective of this study, Vital@Work reintegration program, is to support sick-listed workers with stress-related complaints in their return to work based on a personalized program. Therefore, the aim of this study is test whether participants supported by a tailored eHealth program, and if needed, additionally supported by a structured and stepwise Participatory Approach (PA) involving the sick-listed worker, their direct supervisor and a neutral party, show a faster and sustainable return to work as compared to participants in the control condition. This program is investigated in four different organizations, which differ in sector, size (small and large organizations), type of organization (private or public) and type of work.

Eligibility Criteria

Inclusion Criteria: * Sick-listed employees from participating organisations (Amsterdam UMC, GGZ inGeest, Rijksschoonmaakorganisatie \[RSO\], and Transavia) * Aged 18-68 * Between 2 and 12 weeks on sick leave * Suffering from stress-related complaints Exclusion Criteria: * Non-sick-listed employees * Suffering from severe psychiatric disorders (e.g., suicidality, mania, psychosis, schizophrenia) or other chronic conditions (e.g., terminal illness) that could significantly affect the employee's mental health and, hence, prevent the return-to work process * Being pregnant or less than three months after delivery * Sick-listed for more than 12 weeks * Inability to complete either the eHealth modules or questionnaires * Presence of a legal conflict with the employer * Not signing informed consent

Contact & Investigator

Central Contact

Trees Juurlink, PhD

✉ t.juurlink@amsterdamumc.nl

📞 +31613731701

Frequently Asked Questions

Who can join the NCT06543732 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 68 Years, studying Return to Work. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06543732 currently recruiting?

Yes, NCT06543732 is actively recruiting participants. Contact the research team at t.juurlink@amsterdamumc.nl for enrollment information.

Where is the NCT06543732 trial being conducted?

This trial is being conducted at Amsterdam, Netherlands, Amsterdam, Netherlands, Amsterdam, Netherlands, The Hague, Netherlands.

Who is sponsoring the NCT06543732 clinical trial?

NCT06543732 is sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). The trial plans to enroll 208 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology